TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00131053
Drug: L-asparaginase
Normalized name: L-asparaginase
DrugBank: Asparaginase Escherichia coli (DB00023)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00131053
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02672527
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02672527
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01019746
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol administration
Study: NCT03291249
Drug: Foralumab
Normalized name: Foralumab
DrugBank: Foralumab (DB16170)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti CD3 mAb
Study: NCT03291249
Drug: Omeprazole 20mg
Normalized name: OMEPRAZOLE 20MG CAP,SA
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH
Study: NCT04341428
Drug: Lansoprazole 15 mg
Normalized name: lansoprazole 15 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 15 mg capsule, orally, once daily for up to 24 weeks
Study: NCT04341428
Drug: Lansoprazole 15 mg Placebo
Normalized name: lansoprazole 15 MG
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lansoprazole 15 mg Placebo capsule, orally, once daily for up to 24 weeks
Study: NCT00835211
Drug: Desmopressin Acetate 0.2 mg Tablets
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 x 0.2 mg, single-dose fasting
Study: NCT03219320
Drug: NYX-2925
Normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NYX-2925 is a novel small molecule that modulates the N-methyl-D-aspartate receptor (NMDAR).
Study: NCT00749112
Drug: Alemtuzumab, Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
Study: NCT03608358
Drug: Dapagliflozin 10 mg
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study: NCT03608358
Drug: Dapagliflozin 5 mg
Normalized name: dapagliflozin 5 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study: NCT03608358
Drug: Dapagliflozin 10 mg placebo to match
Normalized name: dapagliflozin 10 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 10 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study: NCT03608358
Drug: Dapagliflozin 5 mg placebo to match
Normalized name: dapagliflozin 5 MG
DrugBank: Dapagliflozin (DB06292)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blind treatment period
Study: NCT03608358
Drug: Saxagliptin 5 mg
Normalized name: sAXagliptin 5 MG
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg, oral tablet, once daily for 24 weeks of double-blinded treatment period, and for 16 weeks of open-label treatment period in Stratum A or 8 weeks of open-label treatment period in Stratum B
Study: NCT03608358
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stable dose of metformin immediate release/extended release (≥ 1500 mg/day or at a maximal tolerated dose) throughout the whole study period
Study: NCT03752424
Drug: Silver nanoparticles
Normalized name: Silver nanoparticles
DrugBank: Silver (DB12965)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The active group will receive silver nanoparticles in different dosage forms as an anti-microbial drug.
Study: NCT03752424
Drug: Topical approved anti-microbial gel
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The placebo group will receive topical FDA approved anti-microbial jel in different dosage forms as control drug.
Study: NCT01431807
Drug: SYR-472
Normalized name: petrolatum 0.472 MG/MG
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, for up to 52 weeks.
Study: NCT03255226
Drug: Tolvaptan
Normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
Study: NCT01099449
Drug: calcium gluconate
Normalized name: Calcium Gluconate
DrugBank: Calcium gluconate (DB11126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01099449
Drug: magnesium sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01099449
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04110535
Drug: Remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: IV administration over 1 minute
Study: NCT04110535
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV administration over 1 minute
Study: NCT01017731
Drug: Moxifloxacin
Normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01017731
Drug: Diphenhydramine
Normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV
Study: NCT03100786
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
Study: NCT00833391
Drug: open label
Normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
Study: NCT03568656
Drug: CCS1477
Normalized name: P300/cbp bromodomain inhibitor ccs1477
DrugBank: Inobrodib (DB17514)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules, oral
Study: NCT03568656
Drug: Abiraterone acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Abiraterone acetate 500mg tablets plus prednisone/prednisolone
Study: NCT03568656
Drug: Enzalutamide
Normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide 40mg capsules/tablets
Study: NCT03568656
Drug: Darolutamide
Normalized name: DAROLUTAMIDE
DrugBank: Darolutamide (DB12941)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300mg tablets
Study: NCT03568656
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 150mg tablets
Study: NCT03568656
Drug: Atezolizumab
Normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 840mg/14ml concentrate for solution for infusion vials
Study: NCT01452100
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight \<70 kg ; or 25mg/d if body weight \>70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
Study: NCT02215980
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02215980
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01536392
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
Study: NCT01536392
Drug: Ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
Study: NCT00934440
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.~* Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.~* Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles).
Study: NCT00934440
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: * Dose level 1: 35 mg/m2/day for 7 days.~* Dose level 2: 55 mg/m2/day for 7 days.~* Dose level 3: 75 mg/m2/day for 7 days.~  * mg/m2/day = dose based on height and weight
Study: NCT01748240
Drug: Azacitidine and oral vorinostat
Normalized name: Vorinostat
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
Study: NCT01590758
Drug: Topical pexiganan cream 0.8%
DrugBank: Pexiganan (DB16293)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 days of treatment
Study: NCT02717832
Drug: hyperinsulinemic-euglycemic clamp
Normalized name: CLAMP
DrugBank: SARS-CoV-2 Sclamp (DB15849)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01818752
Drug: Carfilzomib
Normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
Study: NCT01818752
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
Study: NCT01818752
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
Study: NCT01818752
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
Study: NCT00178113
Drug: - Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)
Normalized name: Padimate O
DrugBank: Padimate O (DB11570)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00004005
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01324141
Drug: Tempol
Normalized name: Tempol
DrugBank: Tempol (DB12449)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of radiation therapy (RT).
Study: NCT01324141
Drug: 5-Fluorouracil
Normalized name: 5-fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 5-FU will be delivered as 1000mg/m(2)/day as 96 hour continuous infusion beginning on day 1 and 29.
Study: NCT01324141
Drug: Mitomycin-C
Normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mitomycin-C (MMC) will be delivered at a dose of 10mg/m(2) on days 1 and 29
Study: NCT00551473
Drug: Lavoltidine
Normalized name: Lavoltidine
DrugBank: Lavoltidine (DB12884)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02644616
Drug: tolvaptan+torasemide
Normalized name: Tolvaptan
DrugBank: Torasemide (DB00214)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
Study: NCT02644616
Drug: placebo+torasemide
DrugBank: Torasemide (DB00214)
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 15mg/d po(10 days) +torasemide 20mg/d iv
Study: NCT01755026
Drug: cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 gram dose for pre-operative prophylaxis
Study: NCT01755026
Drug: cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 gram dose for pre-operative prophylaxis
Study: NCT01214395
Drug: 5% tea tree oil nasal ointment
DrugBank: Tea tree oil (DB11218)
Approvals — FDA: no, EMA: no, PMDA: no
Description: daily for 5 days then weekly for 6 months
Study: NCT03291093
Drug: 18F-Flutemetamol PET/MRI
DrugBank: Flutemetamol (18F) (DB09151)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
Study: NCT00602927
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
Study: NCT00294086
Drug: valsartan 160 mg
Normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00294086
Drug: valsartan 160 mg BID
Normalized name: valsartan 160 MG
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03229694
Drug: Tracleer 125Mg Tablet
Normalized name: Tracleer 125mg Tablet
DrugBank: Bosentan (DB00559)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tracleer was administered orally at two hours before surgery and six hours after surgery.
Study: NCT02459288
Drug: Clopidogrel first
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
Study: NCT02459288
Drug: Ticagrelor first
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
Study: NCT02087007
Drug: Cilostazol
Normalized name: Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
Study: NCT00611754
Drug: Oxaliplatin, 5-FU
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
Study: NCT02215018
Drug: BI 44370 TA solution
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02215018
Drug: BI 44370 TA tablet
Normalized name: BI 44370 TA
DrugBank: BI 44370 TA (DB16037)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00095147
Drug: Infliximab (INF) + MTX, DB
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
Study: NCT00225264
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
Study: NCT00225264
Drug: Glimepiride
Normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
Study: NCT03471624
Drug: Tenofovir Alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (TAF) is a new formulation of tenofovir with higher intracellular active drug concentration allowing for dosing of only 25 mg once daily and thus can potentially lower the already low risk of renal toxicity and bone loss with tenofovir disoproxil fumarate (TDF).
Study: NCT01306929
Drug: pridopidine
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45mg bid
Study: NCT01624246
Drug: Ceftaroline fosamil/Avibactam (CXL)
DrugBank: Ceftaroline fosamil (DB06590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV infusion of CXL (combination of ceftaroline fosamil \[600 mg\] plus avibactam \[600 mg\]) infused over 60 (± 5) minutes.
Study: NCT00181597
Drug: Trilostane
Normalized name: TRILOSTANE
DrugBank: Trilostane (DB01108)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Taken orally once a day for three days then twice daily thereafter.
Study: NCT03810872
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Open label
Study: NCT03810872
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel
Study: NCT02777320
Drug: paracetamol
Normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
Study: NCT00509665
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: given as 100mg/m2 IV over days 1 and 8 of each 21 day cycle
Study: NCT00789867
Drug: pGM169/GL67A
Normalized name: pGM169/GL67A
DrugBank: pGM169/GL67A (DB17917)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Received a nebulized dose via an breath-actuated nebulizer
Study: NCT02774902
Drug: TAK-438
Normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-438 tablets
Study: NCT01226823
Drug: Ursodeoxycholic Acid
Normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
Study: NCT02282293
Drug: Monthly dihydroartemisinin-piperaquine (DP) + daily trimethoprim/sulfamethoxazole (TS)
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02282293
Drug: Monthly placebo + daily trimethoprim/sulfamethoxazole (TS)
DrugBank: Trimethoprim (DB00440)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03927378
Drug: S-ketamine
Normalized name: S-ketamine
DrugBank: Esketamine (DB11823)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S-ketamine (0.2 mg/kg in 20 ml normal saline) is administered by intravenous infusion in 40 minutes after childbirth.
Study: NCT04341727
Drug: Hydroxychloroquine Sulfate
Normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: anti-rheumatic drug (DMARD)
Study: NCT04341727
Drug: Chloroquine Sulfate
Normalized name: Chloroquine sulfate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antimalarial
Study: NCT00088504
Drug: Merimepodib
Normalized name: Merimepodib
DrugBank: Merimepodib (DB04862)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00088504
Drug: PEG-Interferon-alpha 2a (Pegasys®)
Normalized name: Interferon alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00088504
Drug: Ribavirin (Copegus®)
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04711161
Drug: GRN-300
Normalized name: methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A salt-inducible kinase (SIK) inhibitor
Study: NCT04711161
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Microtubule inhibitor
Study: NCT02449343
Drug: Anlotinib
Normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib p.o. qd
Study: NCT01055067
Drug: Tivantinib (ARQ 197)
Normalized name: Tivantinib
DrugBank: Tivantinib (DB12200)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule, 120 mg, BID (360 mg), approximately 112 days
Study: NCT02473146
Drug: Gemtuzumab ozogamicin (GO)
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00831493
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
Study: NCT01227174
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procedural sedation will be achieved using propofol
Study: NCT01550848
Drug: Abraxane and Gemcitabine
Normalized name: Abraxane
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15~GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15
Study: NCT00022646
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00022646
Drug: pemetrexed disodium
Normalized name: Pemetrexed Disodium
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01882218
Drug: Galactose
Normalized name: Galactose
DrugBank: Galactose (DB11735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
Study: NCT01882218
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard liver surgery.